mTOR-mediated nutrient sensing and oxidative stress pathways regulate autophagy: a key mechanism for traditional Chinese medicine to improve diabetic kidney disease

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 23, 2025

Autophagy plays a pivotal role in the pathogenesis of DKD, and mechanistic target rapamycin (mTOR) pathway, which regulates nutrient sensing oxidative stress responses, is key regulator autophagy. Traditional Chinese Medicine (TCM) has garnered attention for its potential to treat DKD by modulating mTOR signaling reducing stress, restoring autophagic function. The objective this study examine how mTOR-mediated regulation impacts autophagy explore TCM modulates these pathways improve condition. A systematic review was conducted using PubMed, Web Science, Wanfang Data, China National Knowledge Infrastructure (CNKI), with search extended December 2024. subject terms included 'diabetic kidney disease,' 'Traditional Medicine,' 'mTOR,' 'nutrient sensing,' 'oxidative stress.' Studies were rigorously screened two investigators. This systematically examines dysfunction highlighting their impact on It further clarifies mechanisms are targeted medicine treatment DKD. summarizes TCM, including monomers (e.g., Astragaloside IV), individual botanical drugs Dendrobium nobile Lindl.), compound formulations Tongluo Digui Decoction), regulate through such as AMP-activated protein kinase (AMPK), mTOR, sirtuins (Sirt), phosphatidylinositol three (PI3K)/Akt/mTOR pathway. formulas share common foundational framework, majority being formulated based therapeutic principles 'Yiqi', 'Yangyin', 'Tongluo', 'Huashi'. shows promise treating unique advantages pathways. However, underlying remain complex warrant investigation.

Language: Английский

Regulatory effect of atorvastatin combined with berberine on PI3K/AKT/FoxO1 signaling pathway in rats with hyperlipidaemia

Xenobiotica, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 8

Published: May 12, 2025

1.Atorvastatin Calcium (AC) is the first line lipid-lowering drug in clinical. Nowadays, combination of AC and BBR often used to treat hyperlipidemia In order determine mechanism, we investigate regulatory atorvastatin combined with berberine on PI3K/Akt/FoxO1 signaling pathway rats hyperlipidemia.2.The rat model was constructed. Meanwhile, liver protective effects were determined by oil red O H&E method. The expression PI3K, Akt FoxO1 examined IHC, WB RT-pCR. level CK LDH serum ELISA.3.The results showed that AKT increased decreased MC group compared NC (P < 0.01). 0.05). lower than group. levels 0.01), but significantly + group(P 0.01).4.The could regulate lipid mediating PI3K/Akt/FoxO1, which providing a new references for treatment hyperlipidemia.

Language: Английский